PharmacoEconomics & Outcomes News

, Volume 817, Issue 1, pp 29–29 | Cite as

Ribociclib cost effective for HR+/HER2− advanced breast cancer

Clinical study


  1. Galve-Calvo E, et al. Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2- advanced or metastatic breast cancer in Spain. ClinicoEconomics and Outcomes Research 2018: 773-790, No. 10, 14 Nov 2018. Available from: URL: CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Personalised recommendations